GIPC PDZ domain containing family member 1Genealiases: C19orf3 · GIPC · GLUT1CBP · Hs.6454 · IIP-1 · NIP
Q-omics provides the consensus-scored GIPC1 profile across patient tissues and cancer cell-line models. GIPC1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, GIPC1 is differentially expressed in 13, with the highest sampling consensus in LIHC. Additionally, GIPC1 protein abundance shows 20,281 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight SKCM, LIHC, and HNSC as cancer lineages where GIPC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GIPC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GIPC1 survival associations across molecular data types. GIPC1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GIPC1 RNA expression–survival associations across cancer types. High GIPC1 expression shows unfavorable associations in SKCM, ACC, KICH, LGG, BRCA and PAAD. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for GIPC1 RNA expression.
This table summarizes GIPC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GIPC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GIPC1 shows lower tumor expression in KIRC and higher tumor expression in LIHC, BLCA, THCA, UCEC and BRCA. The LIHC box plot shows higher GIPC1 RNA expression in tumor versus normal tissue (log2 FC = +1.559, t-test p < 0.001).
This table shows molecular features associated with GIPC1 in patient tissues and cancer cell lines. In patient samples, GIPC1 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, GIPC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and SOFT_TISSUE.
